hVIVO Regulatory News (HVO)

hVIVO plc

("hVIVO" or the "Company")

Appointment of Nominated Adviser and Joint Broker

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.

For further information please contact:

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Existing Board - AIM Rule 17 Disclosure

The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Elaine Sullivan

In addition to the disclosures made in Elaine Sullivan's announcement of appointment on 24 November 2020, the following directorships are disclosed:

Brendan Buckley

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

Cathal Friel

In addition to the disclosures made in the Admission Document dated 9 December 2019, the following directorships are disclosed:

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019: